Meeting
2021 Genitourinary Cancers Symposium
Frequency, management, and resource use of adverse events (AEs) in nonmetastatic castrate-resistant prostate cancer (nmCRPC) patients receiving apalutamide or enzalutamide: A real-world study.
Authors
Shan Jiang
Bayer, Inc., Whippany, NJ
Shan Jiang , Della Varghese , Sreevalsa Appukkuttan , Shelby Corman , Nehemiah Kebede , Kajan Gnanasakthy , Cynthia Macahilig , A. Reginald Waldeck , Arif Hussain
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Localized Disease
Track
Prostate Cancer - Localized
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 217)
DOI
10.1200/JCO.2021.39.6_suppl.217
Abstract #
217
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.
First Author: Alicia K. Morgans
Poster
2023 ASCO Genitourinary Cancers Symposium
Patient (pt) perspective on fatigue and its management for advanced prostate cancer (PC) treated with androgen receptor inhibitors (ARIs).
First Author: Stephen J. Freedland
Poster
2022 ASCO Quality Care Symposium
Adverse events associated with androgen receptor signaling inhibitors in the treatment of prostate cancer: A systematic review and network meta-analysis.
First Author: Brent Cao
Poster
2021 ASCO Annual Meeting
Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial.
First Author: Karim Fizazi